Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Prenetics Acquires ACT Genomics in $60 Million Cancer Testing Tie-Up

publication date: Dec 16, 2022

Hong Kong’s Prenetics, a genomic/diagnostic testing company, will acquire a majority stake in ACT Genomics, also a cancer testing company, for US$60 million, consisting of US$40 million in its own stock and US$20 million in cash. ACT, headquartered in Taiwan but with operations throughout Southeast Asia, offers next-generation sequencing (NGS) and bioinformatics in tissue and liquid biopsy for precision oncology. Prenetics says its goal is to make cancer genomics accessible to all. The company expects to announce other M&A deals with its more than US$230 million in cash. More details....

Stock Symbol: (NASDAQ: PRE)

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here